J. Lovshin

Endocrinology, Diabetes and Metabolism · 2009

A researcher in the Science corpus: 1 paper; trusts 1 researcher and is trusted by 0 researchers here, as inferred from the citation graph.

Subfields

Whom J. Lovshin trusts overall

Their strongest outbound trust, strongest first, inferred from their citations.

  1. D. J. Drucker
  2. John B. Buse

Who trusts J. Lovshin overall

  1. Wook Kim

Papers from J. Lovshin's perspective

Ordered by how strongly the researchers J. Lovshin trusts endorse each paper. Same corpus, a different order for every researcher.

  1. Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study. (The Lancet)
  2. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. (Diabetes Care)
  3. Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. (Diabetes Care)
  4. Glucagon-like peptide-1 infusion improves left ventricular ejection fraction and functional status in patients with chronic heart failure. (Journal of Cardiac Failure)
  5. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. (Diabetes Care)
  6. The biology of incretin hormones. (Cell Metabolism)
  7. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. (The Lancet)
  8. Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group study. (The Lancet)
  9. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. (New England Journal of Medicine)
  10. Discovery of the Once-Weekly Glucagon-Like Peptide-1 (GLP-1) Analogue Semaglutide. (Journal of Medicinal Chemistry)

Their papers